Genmab — December 2014
-
Kigger vi på deres nuværende aftaler, så er det kun med Janssen at de har så mange aftaler at dette overhovedet kunne komme på tale. Der er også nogle af forskningsaftalerne der er med relativt små selskaber, så her ser jeg mere små specifikke aftaler i stil med SA aftalerne på ADC stofferne.
-
Gilead har lige lavet en aftale med ONO omkring deres BKT Inhibitor. samme klasse som Ibrutinib
-
de vil virkelig cancer
-
"With this agreement, Gilead now has compounds targeting four unique signaling pathways associated with B-cell malignancies - PI3K delta, Syk, JAK and BTK," said Norbert W. Bischofberger, PhD, Gilead's Executive Vice President, Research and Development and Chief Scientific Officer.
-
aner det ikke. jo rent getværk
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind